ClinicalTrials.gg
CompletedNCT06324214Updated Oct 15, 2026

Oral Supplementation During PR Participation in COPD

A Phase 2 interventional study of Urolithin A (Mitopure) and Placebo in Copd, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Completed at 3 sites in Canada. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 2, Interventional, and Treatment

How we know

Updated Oct 15, 2026Now CompletedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · McGill University Health Centre/Research Institute of the McGill University Health Centre.

Started
2024
the only one that year
Phase 2
Only one
of the 14
Registered
10th of 14
by date

Among the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the only one that started in 2024, is the only one in phase 2, and was the 10th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pulmonary Disease, Chronic Obstructive by McGill University Health Centre/Research Institute of the McGill University Health Centre, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is a very common and chronic lung condition and is a leading cause of morbidity and death. These patients have persistent breathlessness and exercise intolerance, affecting their ability to carry out routine daily tasks. Standard COPD treatments include medicines/puffers as well as participation in a Pulmonary Rehabilitation (PR) program. PR programs are delivered by a diverse team of healthcare experts in exercise and nutrition. It is possible that an emerging nutritional oral supplement could target the muscular dysfunction seen in patients with COPD in part by promoting better working mitochondria, the energy 'engine' of muscle. A series of recently published studies in sedentary adults and in older adults have demonstrated the safety, tolerability, and potential clinical effectiveness of this supplement.

In this regard, the investigators plan to lead a large randomized controlled trial (RCT) to test whether oral supplementation in patients with COPD who are also participating in a standard PR program will improve overall exercise performance. The investigators will also test muscle strength, cognition, body composition, and other clinically important outcomes such as quality of life. Lastly, the investigators will use muscle tissue from a subgroup of volunteers to investigate the effect on muscle/mitochondrial structure/function.

The focus is actually the critical 'first step' before the larger RCT: a pilot and feasibility study on a smaller number of participants with COPD, as an important proof-of-concept that the larger study can, and should, be conducted.

Read the detailed description

The main objectives for this pilot feasibility study are to document recruitment rates, collect information on participant acceptability of tests, establish the capacity to run the RCT at our site, to demonstrate successful molecular testing of specimens, and to generate pilot data for the outcomes being tested in the larger subsequent RCT.

The overarching goal for the 'larger', future project will be to determine the effect of the oral supplement on exercise capacity, muscle strength, mitochondrial function, health-related quality of life, cognition, symptom burden, and safety/adherence in patients with COPD who are participating in a Pulmonary Rehabilitation program. The goal of the present research project is to complete a pilot and feasibility study testing the same clinical outcomes on a smaller sample of eligible study participants during which participants receive the intervention for 8 weeks.

The primary objective is to determine whether administration of the oral supplement during participation in a standard multi-week in-person Pulmonary Rehabilitation (PR) program is associated with an improvement in exercise endurance capacity in patients with COPD, compared with PR participation and placebo supplementation.

The secondary objectives are to determine the effect of the oral supplement on i) global conditioning and exercise capacity; ii) muscle strength; iii) mitochondrial function; iv) body composition; v) quality of life and burden of disease; vi) cognition; vii) adverse events/complications and adherence, and viii) blood levels of Urolithin A.

We hypothesize that patients with COPD receiving oral supplementation during PR participation will demonstrate an improvement in Constant Work Rate Exercise Test (CRWET) time after 8 weeks when compared to patients with COPD who receive placebo and PR participation.

03

Conditions studied

04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, aged >40, former smokers with ≥10 pack-year smoking history
  2. Post-bronchodilator forced expiratory volume at one second () / forced vital capacity (FVC) ratio \< 0.7, with FEV1 \< 80% (moderate, Global Initiative for Chronic Obstructive Lung Disease '(GOLD) 2') FEV1 \< 50% (severe, 'GOLD 3') or FEV1 \< 30% (very severe, 'GOLD 4')
  3. Baseline 6MWD of ≥50m

Exclusion criteria

Exclusion Criteria:

  1. Inability to participate in a standard PR program
  2. Severe/unstable cardiac disease, neurological or orthopedic conditions which could hinder exercise performance
  3. Inability to provide consent due to language or cognitive barrier
  4. Previous PR participation in the last 12 months, or in a study involving an exercise program in the last 6 months
  5. Experienced an exacerbation of (ECOPD) within the prior 4 weeks
  6. Long-term oxygen therapy use, or maintenance oral use
  7. Presence of pacemaker or implantable cardioverter defibrillator (ICD) (unless participant opts out of bioelectrical impedance assay)
  8. Unwilling to agree to refrain from using, or are found to be using, the following supplementary antioxidant vitamins from 7 days prior to dosing and throughout the treatment period: Coenzyme Q10, resveratrol, and L-carnitine
  9. Unwilling to agree to refrain from using, or are found to be using, the following dietary restrictions from 7 days prior to dosing and throughout the treatment period: pomegranate juice, walnuts, pecans, strawberries, raspberries, and blackberries
  10. Allergy to lecithin, to soy or to sunflower
  11. Pregnant, breastfeeding or planning to become pregnant
  12. Any condition, including but not limited to, the use of anticoagulant, presence of a clotting disorder, allergy to anesthetics such as xylocaine and lidocaine, that is not stable in the opinion of the investigator that could affect the safety of the patient in the study (if participating in muscle group).
  13. Chronic myalgia, fibromyalgia or conditions characterized by regular muscle pain (if participating in muscle biopsy subgroup)
  14. Metal fixation plates or screws in the legs from a previous surgery (if participating in muscle biopsy subgroup)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Placebo comparator
    Placebo Group

    Participants will participate in a standard PR program and will receive placebo.

    Other: Placebo

  • Active comparator
    Intervention (Urolithin A: Mitopure) Group

    Participants will participate in a standard PR program and will receive the oral supplement.

    Dietary Supplement: Urolithin A (Mitopure)

Interventions

  • Dietary supplementUrolithin A SupplementStudies of Urolithin A SupplementUrolithin A Supplement pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Compound belonging to the 'urolithin' class. First discovered over 40 years ago as a gut-derived metabolite in rats and subsequently in humans. A food and dietary ingredient, and more specifically, a post-biotic compound. Derived from ellagitannins, which are present in foods such as pomegranate, berries, and walnuts. An 'inducer' of mitophagy.

  • OtherPlacebo

    Placebo.

06

What researchers measure

Primary outcomes

  1. Primary Feasibility Outcome: Recruitment rate

    The proportion of participants who agree to participate out of the number of all potential participants asked to participate. Recruitment rate represents the primary feasibility outcome of the current pilot RCT.

    Time frame: From study launch to study completion at every visit until post-intervention visit (average week 14)

  2. Constant Work Rate Exercise Test (CWRET)

    Exercise test whereby the workload is constant and is calculated as a percentage of the peak power output observed in the incremental test. CWRET time represents the pre-specified primary outcome of the planned main RCT.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

Secondary outcomes

  1. Feasibility Outcome: Attrition rate

    The percentage of participants who do not complete the study out of all participants randomized. Outcome of the current pilot RCT.

    Time frame: From study launch to study completion at every visit until post-intervention visit (average week 14)

  2. Adherence/Fidelity Outcome: Differences in dosed missed

    The total number of doses missed will be recorded and reported. Outcome of the current pilot RCT.

    Time frame: 8 weeks

  3. Feasibility Outcome: Study test completion rate

    Study test completion rate of each assessment (percentage of participants who complete each assessment). Outcome of the current pilot RCT.

    Time frame: From study launch to study completion at every visit until post-intervention visit (average week 14)

  4. Safety Outcome: Adverse events

    Adverse events (AEs) will be monitored from the signing of the Informed Consent Form (ICF) through completion of study participation. If any AEs do occur, study participants will be followed until symptoms have resolved or have returned to baseline levels. All outstanding AEs will be followed until resolution or until the participant's last study visit.

    Time frame: 14 weeks

  5. 6-Minute Walk Test (6MWT)

    6-Minute Walk Distance (6MWD) obtained on a standard 6MWT.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  6. Quadriceps strength

    4-second maximum quadriceps strength test.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  7. Disease-specific impact on quality of life

    St. George's respiratory questionnaire (SGRQ) score is a patient reported outcome measuring quality of life from 0-100 where higher scores indicate worse quality of life.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  8. Burden of disease

    COPD assessment test (CAT) scores is a patient reported outcome measuring COPD symptom burden from 0-40 where higher scores indicate worse symptom burden.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  9. Body composition

    Dual X-ray absorptiometry (DXA) scan

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  10. Body impedance

    Bioelectrical impedance assay (BIA)

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  11. Isokinetic cycling peak power output (PPO)

    Isokinetic cycling PPO is measured during a ≤10-second cycling effort on a stationary isokinetic bicycle.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  12. Cognition

    Stroop test

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  13. Adherence/Fidelity Outcome: Blood levels of the intervention

    Blood levels of Urolithin A will be collected at the mid-point of the study.

    Time frame: Day 28

  14. Feasibility Outcome: Muscle biopsy volunteer rate

    Proportion of participants who consent to the optional muscle biopsy out of those who also meet eligibility criteria for the optional muscle biopsy.

    Time frame: From study launch to study completion at every visit until post-intervention visit (average week 14)

Other outcomes

  1. Exploratory Outcome: Mitochondrial function

    Fresh samples

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  2. Exploratory Outcome: Muscle histology

    Stains for mitochondrial markers (including succinate dehydrogenase (SDH)): post-intervention in comparison to pre-intervention.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  3. Exploratory Outcome: Specific protein detection

    Targeted Western blot analysis for proteins related to mitochondrial function: post-intervention in comparison to pre-intervention.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  4. Exploratory Outcome: Tissue microscopy

    Transmission electron microscopy for assessment of morphology of mitochondria: post-intervention in comparison to pre-intervention.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  5. Exploratory Outcome: Tissue microscopy

    Transmission electron microscopy for assessment of number of mitochondria: post-intervention in comparison to pre-intervention.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

  6. Exploratory Outcome: RNA analyses

    Specific mRNA transcript changes related to mitochondrial function and whole transcriptome changes: post-intervention in comparison to pre-intervention.

    Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)

07

Study locations

3 sites
  • Centre d'Expertise en Maladies Chroniques (CEMC)
    Longueuil, Quebec, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A 3J1, Canada
  • Mount Sinai Hospital
    Montreal, Quebec, Canada
08

References and documents

Individual participant data

Plan to share: No — Due to data privacy regulations, individual participant data collected during this study is not publicly accessible. However, access to anonymized data may be granted upon evaluation by the trial management group. Additional documents will also be available upon inquiry. All requests should be directed to the Principal Investigator (BAR).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Jul 2026, 28 months.

Of 47 non-industry phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 28 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Mar 2025 → Jul 2026 and completion May 2025 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 21, 2024
StartActual
Mar 11, 2024
Primary completionActual
Jul 29, 2026was Mar 2025
CompletionActual
Jul 29, 2026was May 2025
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 15, 2026
Sites
3 sites added, 1 site removed
Show 3 added (3 Canada)
  • Centre d'Expertise en Maladies Chroniques (CEMC) · Longueuil, Canada
  • McGill University Health Centre · Montreal, Canada
  • Mount Sinai Hospital · Montreal, Canada
Show 1 removed
  • McGill University Health Centre · Montréal, Canada
Oct 15, 2026
Primary completion
Mar 4, 2025→Jul 29, 2026 (actual)
Oct 15, 2026
Study completion
May 31, 2025→Jul 29, 2026 (actual)
Oct 15, 2026
Enrollment
10 (estimated)→22 (actual)
Oct 15, 2026
Eligibility
1 inclusion criterion removed; 1 exclusion criterion added, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedPrior receipt of at least 2 doses of the Coronavirus Disease of 2019 (COVID-19) vaccine
Exclusion criteria
  • RemovedUse of anticoagulant or presence of a clotting disorder (if participating in muscle biopsy subgroup)
  • RemovedAllergy to anesthetics such as xylocaine and lidocaine (if participating in muscle biopsy subgroup)
  • AddedAny condition, including but not limited to, the use of anticoagulant, presence of a clotting disorder, allergy to anesthetics such as xylocaine and lidocaine, that is not stable in the opinion of the investigator that could affect the safety of the patient in the study (if participating in muscle biopsy group).
Oct 15, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedConstant Work Rate Exercise Test (CRWETCWRET)Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • AddedPrimary Feasibility Outcome: Recruitment rateTime frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
Oct 15, 2026
Secondary outcomes
3 edited, 10 added, 6 removed, 4 description edited
What changed in the outcomes
  • EditedSafety Outcome: Adverse eventsTime frame: 12 weeks → 14 weeks
  • EditedAdherence/Fidelity Outcome: Differences in dosed missedTime frame: 8 weeks
  • EditedAdherence/Fidelity Outcome: Blood levels of the interventionTime frame: Day 28
  • AddedFeasibility Outcome: Attrition rateTime frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
  • AddedFeasibility Outcome: Study test completion rateTime frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
  • AddedIsokinetic cycling peak power output (PPO)Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • AddedFeasibility Outcome: Muscle biopsy volunteer rateTime frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
  • RemovedMitochondrial functionTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • RemovedMuscle histologyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • RemovedTissue microscopyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • RemovedTissue microscopyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • RemovedSpecific protein detectionTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • RemovedRNA analysesTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • Description6-Minute Walk Test (6MWT): how it is measured was reworded
  • DescriptionBurden of disease: how it is measured was reworded
  • DescriptionDisease-specific impact on quality of life: how it is measured was reworded
  • DescriptionQuadriceps strength: how it is measured was reworded
  • Addedother outcomeExploratory Outcome: Mitochondrial functionTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • Addedother outcomeExploratory Outcome: Muscle histologyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • Addedother outcomeExploratory Outcome: Specific protein detectionTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • Addedother outcomeExploratory Outcome: Tissue microscopyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • Addedother outcomeExploratory Outcome: Tissue microscopyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
  • Addedother outcomeExploratory Outcome: RNA analysesTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Completed
    3 sites added, 1 site removed
    Show 3 added (3 Canada)
    • Centre d'Expertise en Maladies Chroniques (CEMC) · Longueuil, Canada
    • McGill University Health Centre · Montreal, Canada
    • Mount Sinai Hospital · Montreal, Canada
    Show 1 removed
    • McGill University Health Centre · Montréal, Canada
    Primary completion Mar 4, 2025→Jul 29, 2026 (now actual)
    Study completion May 31, 2025→Jul 29, 2026 (now actual)
    Enrollment 10 (estimated)→22 (actual)
    Eligibility 1 inclusion criterion removed; 1 exclusion criterion added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedPrior receipt of at least 2 doses of the Coronavirus Disease of 2019 (COVID-19) vaccine
    Exclusion criteria
    • RemovedUse of anticoagulant or presence of a clotting disorder (if participating in muscle biopsy subgroup)
    • RemovedAllergy to anesthetics such as xylocaine and lidocaine (if participating in muscle biopsy subgroup)
    • AddedAny condition, including but not limited to, the use of anticoagulant, presence of a clotting disorder, allergy to anesthetics such as xylocaine and lidocaine, that is not stable in the opinion of the investigator that could affect the safety of the patient in the study (if participating in muscle biopsy group).
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedConstant Work Rate Exercise Test (CRWETCWRET)Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • AddedPrimary Feasibility Outcome: Recruitment rateTime frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
    Secondary outcomes 3 edited, 10 added, 6 removed, 4 description edited
    What changed in the outcomes
    • EditedSafety Outcome: Adverse eventsTime frame: 12 weeks → 14 weeks
    • EditedAdherence/Fidelity Outcome: Differences in dosed missedTime frame: 8 weeks
    • EditedAdherence/Fidelity Outcome: Blood levels of the interventionTime frame: Day 28
    • AddedFeasibility Outcome: Attrition rateTime frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
    • AddedFeasibility Outcome: Study test completion rateTime frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
    • AddedIsokinetic cycling peak power output (PPO)Time frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • AddedFeasibility Outcome: Muscle biopsy volunteer rateTime frame: From study launch to study completion at every visit until post-intervention visit (average week 14)
    • RemovedMitochondrial functionTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • RemovedMuscle histologyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • RemovedTissue microscopyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • RemovedTissue microscopyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • RemovedSpecific protein detectionTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • RemovedRNA analysesTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • Description6-Minute Walk Test (6MWT): how it is measured was reworded
    • DescriptionBurden of disease: how it is measured was reworded
    • DescriptionDisease-specific impact on quality of life: how it is measured was reworded
    • DescriptionQuadriceps strength: how it is measured was reworded
    • Addedother outcomeExploratory Outcome: Mitochondrial functionTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • Addedother outcomeExploratory Outcome: Muscle histologyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • Addedother outcomeExploratory Outcome: Specific protein detectionTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • Addedother outcomeExploratory Outcome: Tissue microscopyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • Addedother outcomeExploratory Outcome: Tissue microscopyTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    • Addedother outcomeExploratory Outcome: RNA analysesTime frame: Pre-intervention (baseline) and Post-intervention (after 8 weeks)
    + 5 other changes: verification date, responsible party, contact details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06324214
Collaborators
Amazentis SA
Responsible party
Bryan A. Ross (Principal Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre) — Principal investigator
First posted
Mar 21, 2024
Start date
Mar 11, 2024
Primary completion
Jul 29, 2026
Completion
Jul 29, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Urolithin A Supplement

Start the discussion